Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in dense red cells in sickle cell disease · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effects of K‐Cl cotransport red cell K+ and Mg2+ content (RBC magnesium) mM/kg Hb · people with sickle cell disease
1 finding from 1 review
Adverse events: diarrhoea and headache · people with sickle cell disease
1 finding from 1 review
Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease
1 finding from 1 review
Change in frequency of vaso‐occlusive painful crises (as measured by pain diary days with significant pain) · people with sickle cell disease
1 finding from 1 review
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Direct costs (medication, hospital bed days) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
The review found no eligible studies for this question.
1 finding from 1 review
Number of individuals with eating difficulties (8 days after administration); duration of eating difficulties · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with eating difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Difficulty in drinking (number with drinking difficulties) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with drinking difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of individuals admitted to hospital after administration · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir showed no clear difference in number of individuals admitted to hospital after administration compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Duration of fever · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review